June 26, 2017 3:35 PM ET

Healthcare Equipment and Supplies

Company Overview of Paragon Vision Sciences, Inc.

Company Overview

Paragon Vision Sciences, Inc. manufactures corneal reshaping, specialty contact lenses, as well as oxygen permeable contact lens materials. It offers CRT contact lenses that enable eye care professionals to treat myopia and corneal refractive therapy. It sells its products through laboratory partners and distributors around the globe. Paragon Vision Sciences, Inc. was formerly known as Paragon Optical Inc. The company was founded in 1976 and is headquartered in Mesa, Arizona. As of May 8, 2015, Paragon Vision Sciences, Inc. operates as a subsidiary of Valeant Pharmaceuticals International, Inc.

947 East Impala Avenue

Mesa, AZ 85204-6619

United States

Founded in 1976





Key Executives for Paragon Vision Sciences, Inc.

Chief Executive Officer
Chief Financial Officer and Vice President of Finance & Operations
Vice President of Sales & Business Development of Europe, Middle East and Africa
Vice President of Marketing, US & Canada
Compensation as of Fiscal Year 2016.

Paragon Vision Sciences, Inc. Key Developments

Paragon Vision Sciences Receives Paragon CRT Contact Lenses Approval from China Food and Drug Administration

Paragon Vision Sciences announced China Food and Drug Administration approval and commercial availability of its corneal reshaping/orthokeratology brand, Paragon CRT Contact Lenses in China. The contact lenses, a non-surgical treatment option for managing myopia (nearsightedness) are now available in 50 countries around the world, including the United States. Orthokeratology is a non-surgical, option used to treat nearsightedness and low degrees of astigmatism using therapeutic contact lenses worn overnight. While asleep, the lenses gently reshape the front surface of the eye (cornea), resulting in clear vision the following day after the therapeutic CRT lenses are removed. Essilor China will serve as the exclusive distributor for Paragon CRT Contact Lenses in China. The lenses will be widely available to eye care practitioners within the next few months.

Valeant Pharmaceuticals Reportedly Selling Paragon

Valeant Pharmaceuticals International, Inc. (NYSE:VRX) is reaching out to potential buyers for Paragon Vision Sciences, Inc., amid scrutiny from the Federal Trade Commission, according to two people familiar with the matter. It is unclear whether the process will result in a sale and the identity of the potential buyers is unknown. A spokesperson for Valeant said Valeant does not comment on market rumors or speculation and noted that Valeant is cooperating fully with Federal Trade Commission.

Similar Private Companies By Industry

Company Name Region
.decimal, Inc. United States
20/20 GeneSystems, Inc. United States
20/20 Imaging LLC United States
21st Century Scientific, Inc. United States
21X Corporation United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Paragon Vision Sciences, Inc., please visit www.paragonvision.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.